Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Savient Pharmaceuticals Inc.

Division of Horizon Therapeutics PLC
www.savientpharma.com

Latest From Savient Pharmaceuticals Inc.

A Penny Saved: Why Delaying 340B Pricing Rule Is Good News For Companies Like Horizon

HRSA proposes another delay to effective date of final rule on calculating the ceiling prices for drugs sold to 340B program. Agency also appears ready to reconsider the 'penny pricing' policy that rule would codify.

Market Access Healthcare Systems

With Zurampic, FDA Again Made Do With Sorry State Of Regulatory Science In Gout

Zurampic, which AstraZeneca licensed to Ironwood, pushed the limits of FDA's tolerance of the regulatory compromises agency has had to make in gout; our Drug Review Profile shows how statistician's case against approval received serious consideration, although the agency ultimately valued consistency with previous approvals in the space.

Regulation Drug Review

'Conflicted' Panel Backs AZ Gout Drug; Market Potential?

The FDA's Arthritis Advisory Committee (AAC) on Oct. 23 in a 10-4 vote recommended approval of lesinurad, an experimental drug from AstraZeneca plc and its US unit Ardea Biosciences Inc., as a treatment in combination with a xanthine oxidase inhibitor (XOI), such as allopurinol or febuxostat, for hyperuricemia associated with gout in adults.

Gynecology & Urology Orthopedics

Basilea names new commercial head

Basilea Pharmaceutica, which develops products in the therapeutic areas of bacterial infections, fungal infections and oncology, has named David Veitch chief commercial officer – effective 1 September 2014. Mr Veitch will be responsible for leading Basilea's commercial operations, including sales, marketing, pricing and market access, and will report to chief executive officer Ronald Scott. Prior to joining the Basel, Switzerland-based firm, Mr Veitch was president of European operations at Savient Pharmaceuticals.

Switzerland
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Bio-Technology General Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Horizon Therapeutics PLC
  • Senior Management
  • John P Hamill, Co-Pres. & CFO
    Richard Crowley, Co-Pres. & COO
    Philip K Yachmetz, Chief Bus. Officer
    Kenneth M Bahrt, MD, SVP, CMO
  • Contact Info
  • Savient Pharmaceuticals Inc.
    Phone: (732) 418-9300
    400 Crossing Blvd.
    Bridgewater, NJ 08807
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register